M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Promoting HPV Vaccination Among Young Adults in Texas

Not Applicable

Active, not recruiting

Conditions: Human Papillomavirus Infection

Interventions: Other: Informational Intervention
Other: Enhancing Accessibility to Health Care
Other: Interview
Other: Questionnaire Administration

First Posted Date: 2021-09-27

Last Posted Date: 2025-05-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1200

Registration Number: NCT05057312

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge

Not Applicable

Recruiting

Conditions: Breast Carcinoma

Interventions: Procedure: Contrast Enhanced Digital Mammography
Procedure: Digital Tomosynthesis Mammography
Drug: Iodinated Contrast Agent
Other: Questionnaire Administration

First Posted Date: 2021-09-27

Last Posted Date: 2025-04-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 66

Registration Number: NCT05056844

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer

Active, not recruiting

Conditions: Locally Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Metastatic Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
COVID-19 Infection
Recurrent Hematologic Malignancy
Recurrent Malignant Solid Neoplasm

Interventions: Other: Survey Administration

First Posted Date: 2021-09-27

Last Posted Date: 2024-03-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 223

Registration Number: NCT05058339

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

PREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema

Not Applicable

Active, not recruiting

Conditions: Lymphedema

Interventions: Other: Cohort II (patients followed intensively for lymphedema)
Other: Cohort I (patients receiving annual lymphedema screening

First Posted Date: 2021-09-24

Last Posted Date: 2025-03-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 260

Registration Number: NCT05056207

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer

Not Applicable

Active, not recruiting

Conditions: Prostate Carcinoma
Prostate Adenocarcinoma

Interventions: Procedure: Magnetic Resonance Imaging

First Posted Date: 2021-09-24

Last Posted Date: 2025-04-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT05055843

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR

Early Phase 1

Withdrawn

Conditions: Brain Metastases
Glioblastoma
Gliomas
Cancer

Interventions: Drug: F18 Fluciclovine
Other: Standard of Care

First Posted Date: 2021-09-23

Last Posted Date: 2023-09-01

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05054400

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Phase 1

Recruiting

Conditions: Myeloma

Interventions: Drug: Belantamab mafodotin

First Posted Date: 2021-09-23

Last Posted Date: 2025-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05055063

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method

Recruiting

Conditions: Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Questionnaire Administration

First Posted Date: 2021-09-23

Last Posted Date: 2025-05-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT05054413

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630

Phase 1

Suspended

Conditions: Bladder
Bladder Cancer

Interventions: Drug: UGN-201

First Posted Date: 2021-09-23

Last Posted Date: 2025-03-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT05055050

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases

Phase 4

Completed

Conditions: Metastatic Malignant Solid Neoplasm
Metastatic Malignant Neoplasm in the Brain

Interventions: Radiation: Fludeoxyglucose F-18
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2021-09-23

Last Posted Date: 2024-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT05054998

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy